Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults

* INCLUSION CRITERIA: 1. 18 to 35 years old 2. Available for clinic visits for 24 months after enrollment 3. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process 4. Able and willing to complete the informed consent process 5. Willing to donate blood for sample storage to be used for future research 6. In good general health without clinically significant medical history 7. Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) less than or equal to 40 within the 56 days prior to enrollment 8. Agrees not to receive licensed or investigational flavivirus vaccines through 4 weeks after last study injection INCLUSION CRITERIA - LABORATORY CRITERIA WITHIN 56 DAYS PRIOR TO ENROLLMENT: 9. Hemoglobin within institutional normal limits or accompanied by the site PI or designee approval 10. WBC and differential either within institutional normal range or accompanied by site PI or designee approval 11. Total lymphocyte count greater than or equal to 800 cells/mm\^3 12. Platelets = 125,000 - 500,000/mm\^3 13. Alanine aminotransferase (ALT) less than or equal to 1.25 x institutional upper limit of normal (ULN) 14. Serum creatinine less than or equal to 1.1 x institutional ULN 15. Negative for HIV infection by an FDA approved method of detection INCLUSION CRITERIA - CRITERIA APPLICABLE TO WOMEN OF CHILDBEARING POTENTIAL: 16. Negative human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on day of enrollment 17. Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 12 weeks after the last study vaccination EXCLUSION CRITERIA - FEMALE-SPECIFIC: 1. Breast-feeding or planning to become pregnant while participating through 12 weeks after the last study vaccination EXCLUSION CRITERIA - SUBJECT HAS RECEIVED ANY OF THE FOLLOWING: 2. More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment 3. Blood products within 16 weeks prior to enrollment 4. Inactivated vaccines within 2 weeks prior to enrollment 5. Live attenuated vaccines within 4 weeks prior to enrollment 6. Investigational research products within 4 weeks prior to enrollment or planning to receive investigational products while on the study 7. Current allergen immunotherapy with antigen injections, unless on maintenance schedule 8. Current anti-TB prophylaxis or therapy EXCLUSION CRITERIA - SUBJECT HAS A HISTORY OF ANY OF THE FOLLOWING CLINICALLY SIGNIFICANT CONDITIONS: 9. Laboratory confirmed ZIKV infection by self-report 10. Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the site investigator 11. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema 12. Asthma that is not well controlled 13. Diabetes mellitus (type I or II), with the exception of gestational diabetes 14. Evidence of autoimmune disease or immunodeficiency 15. Idiopathic urticaria within the past year 16. Hypertension that is not well controlled 17. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws 18. Malignancy that is active or history of malignancy that is likely to recur during the period of the study 19. Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years 20. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen 21. Guillain-Barre Syndrome, Bell s palsy or similar neurological conditions 22. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within 5 years prior to enrollment, a history of suicide plan or attempt 23. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent